First Patient Successfully Treated with Materialise’s X-Ray Based Knee Guide Technology
"The ability to work from X-ray images will make the surgical preplanning process even more efficient. This is because, in many instances, patients will no longer have to undergo an often time-consuming CT or MRI scan, lead times will become shorter, and more cases will become eligible for preoperative planning."
"At Materialise, we initiated the R&D program that is at the source of our new X-ray based technology shortly after the successful introduction of our CT/MRI based guide technology. The reason for this is our continued drive to stay one step ahead of the industry," says Fried Vancraen, the company’s CEO.
"We consider the first treatment of a patient with our X-ray technology as an important landmark in this development program."
Materialise intends to continue evaluating the X-ray based knee guide technology, starting with a limited release of the product in Europe, before then initiating the regulatory clearance process in the US.
With its headquarters in Leuven, Belgium, and branches worldwide, Materialise is a provider of Additive Manufacturing (AM) software solutions and sophisticated 3D printing services in a wide variety of industries, including healthcare, automotive, aerospace, art and design and consumer products. Materialise has been playing an active role in the field of AM since 1990, through its involvement in AM for industrial and medical applications; by providing biomedical and clinical solutions such as medical image processing and surgical simulations and by developing unique solutions for its customers’ prototyping, production, and medical needs.
Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.